Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock Has Average Target Price of $291.25 According to Brokerages

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received a consensus rating of “Buy” from the twenty analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $291.25.

Several analysts recently issued reports on JAZZ shares. Wells Fargo & Company increased their price target on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Citigroup initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They set a “buy” rating and a $325.00 price objective for the company. Barclays upped their target price on Jazz Pharmaceuticals from $270.00 to $271.00 and gave the stock an “overweight” rating in a research note on Thursday, September 10th. Finally, TD Cowen upped their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th.

Jazz Pharmaceuticals Trading Down 0.9%

JAZZ opened at $208.43 on Thursday. Jazz Pharmaceuticals has a twelve month low of $128.80 and a twelve month high of $266.38. The company has a 50-day simple moving average of $238.78 and a 200 day simple moving average of $232.41. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $13.53 billion, a price-to-earnings ratio of 14.37, a P/E/G ratio of 0.21 and a beta of 0.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The company’s quarterly revenue was up 15.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($8.25) earnings per share. Analysts predict that Jazz Pharmaceuticals will post 21.59 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the sale, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This represents a 2.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the sale, the executive vice president directly owned 65,686 shares in the company, valued at $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 100,121 shares of company stock worth $24,855,802. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. CWA Asset Management Group LLC raised its position in Jazz Pharmaceuticals by 24.3% in the third quarter. CWA Asset Management Group LLC now owns 24,384 shares of the specialty pharmaceutical company’s stock valued at $5,645,000 after purchasing an additional 4,765 shares during the last quarter. USA Financial Formulas acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at about $194,000. Aspiriant LLC bought a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $202,000. Pension & Wealth Management Advisors Inc. bought a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $32,000. Finally, Curated Wealth Partners LLC acquired a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $211,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.